Domenico Valerio
Oprichter bij PROQR THERAPEUTICS N.V.
Vermogen: 1 M $ op 31-05-2024
Oorsprong van het eerstegraads netwerk van Domenico Valerio
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
University of Leiden
112
| College/University | Other Consumer Services | 112 |
| Public Company | Pharmaceuticals: Major | 30 | |
Biocartis SA
 Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.
19
| Subsidiary | Medical Specialties | 19 |
University of Amsterdam
14
| College/University | Other Consumer Services | 14 |
Aescap Venture Management BV
 Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector.
9
| Private Company | Investment Managers | 9 |
Leyden Laboratories B.V.
 Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation.
9
| Holding Company | Miscellaneous Commercial Services | 9 |
Amylon Therapeutics BV
 Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Domenico Valerio via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member Chairman Director/Board Member Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer Chief Operating Officer Director/Board Member | |
| Ghent University | College/University | Undergraduate Degree Graduate Degree Graduate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| GALAPAGOS NV | Biotechnology | Chairman Director/Board Member Founder Founder President Director/Board Member | |
| Erasmus University Rotterdam | College/University | Undergraduate Degree Masters Business Admin Corporate Officer/Principal Undergraduate Degree Graduate Degree | |
Impatients NV
 Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer Founder Director/Board Member Chairman Human Resources Officer | |
| Nyenrode Business Universiteit | College/University | Corporate Officer/Principal Undergraduate Degree Undergraduate Degree Director/Board Member | |
| MDXHEALTH SA | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member Chairman | |
| Katholieke Universiteit Leuven | College/University | Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree | |
| University of Twente | College/University | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| The Trustees of Columbia University in The City of New York | College/University | Undergraduate Degree Masters Business Admin Graduate Degree | |
| AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member Chief Operating Officer | |
| Maastricht University | College/University | Chief Tech/Sci/R&D Officer Doctorate Degree Graduate Degree | |
| ABLYNX | Biotechnology | Chairman Director/Board Member Corporate Officer/Principal | |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Medical Specialties | Founder Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| University of Antwerp | College/University | Graduate Degree Graduate Degree Graduate Degree | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Executive Officer Corporate Officer/Principal Sales & Marketing | |
| University of Groningen | College/University | Doctorate Degree Corporate Officer/Principal Undergraduate Degree | |
| University of Pennsylvania | College/University | Doctorate Degree Doctorate Degree | |
| X4 PHARMACEUTICALS, INC. | Biotechnology | Founder Director/Board Member | |
Arrakis Therapeutics, Inc.
 Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Founder Founder | |
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
| University of London | College/University | Corporate Officer/Principal Doctorate Degree | |
| KUROS BIOSCIENCES AG | Biotechnology | Founder Chairman | |
| New York University | College/University | Corporate Officer/Principal Graduate Degree | |
| Institute For Human Organ & Disease Model Technologies | Director/Board Member Chief Executive Officer | ||
Artax Biopharma, Inc.
 Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Medical Specialties | Director/Board Member Director/Board Member | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Chairman Director/Board Member | |
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Private Equity Investor | |
RespiVert Ltd.
 RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Medical Distributors | Director/Board Member Chairman | |
Galapagos Biotech Ltd.
 Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
| ABN AMRO BANK N.V. | Major Banks | Director/Board Member Human Resources Officer | |
| BLUEPRINT MEDICINES CORPORATION | Biotechnology | Director/Board Member Director/Board Member | |
| GILEAD SCIENCES, INC. | Biotechnology | Director/Board Member Treasurer | |
| DENALI THERAPEUTICS INC. | Biotechnology | Director/Board Member Director/Board Member | |
AlpInvest Partners BV
 AlpInvest Partners BV Investment ManagersFinance AlpInvest Partners BV (AlpInvest) is a private equity asset subsidiary AP BV, ultimately owned by The Carlyle Group, Inc founded in 2000. AlpInvest Partners BV is headquartered in Amsterdam, the Netherlands. | Investment Managers | Chief Executive Officer Private Equity Investor | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree | |
| PRIME MEDICINE, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| University of Utrecht | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| VERASTEM, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Janssen Vaccines & Prevention BV
 Janssen Vaccines & Prevention BV Pharmaceuticals: MajorHealth Technology Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer General Counsel |
Statistieken
Internationaal
| Verenigde Staten | 17 |
| Nederland | 15 |
| België | 12 |
| Verenigd Koninkrijk | 6 |
| Zwitserland | 3 |
Sectoraal
| Health Technology | 29 |
| Consumer Services | 15 |
| Finance | 5 |
| Commercial Services | 3 |
| Distribution Services | 2 |
Operationeel
| Director/Board Member | 516 |
| Corporate Officer/Principal | 182 |
| Chairman | 88 |
| Independent Dir/Board Member | 87 |
| Chief Executive Officer | 68 |
Sterkste connecties
| Insiders | |
|---|---|
| Raj Bhikhu Parekh | 50 |
| Antoine Papiernik | 48 |
| Henri A. Termeer | 42 |
| Stephen Knight | 39 |
| Bo Jesper Hansen | 34 |
| Rudi Mariën | 31 |
| Patrick Volkert Vink | 30 |
| Annemieke J. M. Roobeek | 29 |
| Alison Lawton | 25 |
| James Shannon | 23 |
| Patrick Johan Hendrik Krol | 22 |
| Staf van Reet | 22 |
| Bote de Vries | 22 |
| Rudi Pauwels | 19 |
| Joost Hessel Louis Bergsma | 19 |
- Beurs
- Insiders
- Domenico Valerio
- Bedrijfsconnecties
